Vincent T, Zhu M, Parekh A, Patel U, Cloney-Clark S, Klindworth A
Microorganisms. 2024; 12(11).
PMID: 39597746
PMC: 11596312.
DOI: 10.3390/microorganisms12112358.
Lou J, Liang W, Cao L, Hu I, Zhao S, Chen Z
Nat Commun. 2024; 15(1):2546.
PMID: 38514647
PMC: 10958014.
DOI: 10.1038/s41467-024-46918-0.
Zhao S, Schuurman N, Tieke M, Quist B, Zwinkels S, van Kuppeveld F
J Clin Microbiol. 2020; 58(11).
PMID: 32878956
PMC: 7587082.
DOI: 10.1128/JCM.01689-20.
Lee E, Tian H, Nakaya H
Hum Vaccin Immunother. 2020; 16(11):2690-2708.
PMID: 32750260
PMC: 7734114.
DOI: 10.1080/21645515.2020.1734397.
VanDalen K, Shriner S, Sullivan H, Root J, Franklin A
Mamm Rev. 2020; 39(3):167-177.
PMID: 32367904
PMC: 7194294.
DOI: 10.1111/j.1365-2907.2009.00144.x.
Mammalian pathogenicity and transmissibility of a reassortant Eurasian avian-like A(H1N1v) influenza virus associated with human infection in China (2015).
Pulit-Penaloza J, Belser J, Tumpey T, Maines T
Virology. 2019; 537:31-35.
PMID: 31430632
PMC: 9608380.
DOI: 10.1016/j.virol.2019.08.008.
Are Microneutralization and Hemagglutination Inhibition Assays Comparable? Serological Results from Influenza Experimentally Infected Mallard Ducks.
Segovia K, Franca M, Bahnson C, Latorre-Margalef N, Stallknecht D
Avian Dis. 2019; 63(sp1):138-144.
PMID: 31131570
PMC: 7213506.
DOI: 10.1637/11886-042718-Reg.1.
Swine-Origin H1 Influenza Viruses Isolated from Humans Exhibit Sustained Infectivity in an Aerosol State.
Pulit-Penaloza J, Belser J, Tumpey T, Maines T
Appl Environ Microbiol. 2019; 85(10).
PMID: 30877121
PMC: 6498153.
DOI: 10.1128/AEM.00210-19.
Impact of erythrocyte species on assays for influenza serology.
Trombetta C, Ulivieri C, Cox R, Remarque E, Centi C, Perini D
J Prev Med Hyg. 2018; 59(1):E1-E7.
PMID: 29938233
PMC: 6009068.
DOI: 10.15167/2421-4248/jpmh2018.59.1.870.
Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects.
Olafsdottir T, Alexandersson K, Sveinbjornsson G, Lapini G, Palladino L, Montomoli E
Front Immunol. 2018; 8:1872.
PMID: 29358933
PMC: 5766658.
DOI: 10.3389/fimmu.2017.01872.
The Comparison of Sensitivity and Specificity of ELISA-based Microneutralization Test with Hemagglutination Inhibition Test to Evaluate Neutralizing Antibody against Influenza Virus (H1N1).
Tavakoli A, Rezaei F, Fatemi Nasab G, Adjaminezhad-Fard F, Noroozbabaei Z, Mokhtari-Azad T
Iran J Public Health. 2017; 46(12):1690-1696.
PMID: 29259944
PMC: 5734969.
An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.
Jones E, Amoah S, Cao W, Sambhara S, Gangappa S
J Infect Dis. 2017; 216(suppl_4):S560-S565.
PMID: 28934453
PMC: 5737928.
DOI: 10.1093/infdis/jiw585.
Influenza A Virus Studies in a Mouse Model of Infection.
Rodriguez L, Nogales A, Martinez-Sobrido L
J Vis Exp. 2017; (127).
PMID: 28930978
PMC: 5752200.
DOI: 10.3791/55898.
A highly immunogenic vaccine against A/H7N9 influenza virus.
Cao W, Liepkalns J, Hassan A, Kamal R, Hofstetter A, Amoah S
Vaccine. 2016; 34(6):744-9.
PMID: 26765287
PMC: 4735641.
DOI: 10.1016/j.vaccine.2015.12.062.
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
Stavaru C, Onu A, Lupulescu E, tucureanu C, Rasid O, Vlase E
Hum Vaccin Immunother. 2015; 12(4):1009-26.
PMID: 26618392
PMC: 5036962.
DOI: 10.1080/21645515.2015.1111495.
Development and applications of single-cycle infectious influenza A virus (sciIAV).
Nogales A, Baker S, Domm W, Martinez-Sobrido L
Virus Res. 2015; 216:26-40.
PMID: 26220478
PMC: 4728073.
DOI: 10.1016/j.virusres.2015.07.013.
Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.
Pedersen G, Sjursen H, Nostbakken J, Jul-Larsen A, Hoschler K, Cox R
Hum Vaccin Immunother. 2014; 10(8):2408-16.
PMID: 25424948
PMC: 4896793.
DOI: 10.4161/hv.29583.
Fast vaccine design and development based on correlates of protection (COPs).
van Els C, Mjaaland S, Naess L, Sarkadi J, Gonczol E, Korsholm K
Hum Vaccin Immunother. 2014; 10(7):1935-48.
PMID: 25424803
PMC: 4186026.
DOI: 10.4161/hv.28639.
Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/H1N1.
Ovsyannikova I, White S, Albrecht R, Garcia-Sastre A, Poland G
Viral Immunol. 2014; 27(4):174-8.
PMID: 24787023
PMC: 4025626.
DOI: 10.1089/vim.2013.0111.
A combination of serological assays to detect human antibodies to the avian influenza A H7N9 virus.
Dong L, Bo H, Bai T, Gao R, Dong J, Zhang Y
PLoS One. 2014; 9(4):e95612.
PMID: 24755627
PMC: 3995704.
DOI: 10.1371/journal.pone.0095612.